Hepion Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Hepion Pharmaceuticals

22/11/2023 11:33

* Hepion Pharmaceuticals Inc  HEPA.OQ  reported a quarterly
adjusted loss of $2.74​​ per share for the quarter ended in
September, lower than the same quarter last year, when the
company reported EPS of $-2.20.  The mean expectation of
two analysts for the quarter was for a loss of $3.12 per share.
Wall Street expected results to range from $-3.56 to $-2.68 per
share.
    * Reported revenue was zero​. 
    * Hepion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.74​.
    * The company reported a quarterly loss of $10.53 million.
    * Hepion Pharmaceuticals Inc shares had fallen by 37.7% this
quarter and lost 48.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 90.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Hepion
Pharmaceuticals Inc is $26.00 

This summary was machine generated from LSEG data November 22 at
11:32 a.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -3.12          -2.74          Beat
 Jun. 30 2023      -3.32          -3.68          Missed
 Mar. 31 2023      -3.60          -3.48          Beat
 Dec. 31 2022      -2.60          -2.60          Met